153 related articles for article (PubMed ID: 9393947)
1. The role of estrogen receptor mutations in tamoxifen-stimulated breast cancer.
Tonetti DA; Jordan VC
J Steroid Biochem Mol Biol; 1997 Jun; 62(2-3):119-28. PubMed ID: 9393947
[TBL] [Abstract][Full Text] [Related]
2. Third annual William L. McGuire Memorial Lecture. "Studies on the estrogen receptor in breast cancer"--20 years as a target for the treatment and prevention of cancer.
Jordan VC
Breast Cancer Res Treat; 1995; 36(3):267-85. PubMed ID: 8573710
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of tamoxifen resistance in the treatment of advanced breast cancer.
Lykkesfeldt AE
Acta Oncol; 1996; 35 Suppl 5():9-14. PubMed ID: 9142958
[TBL] [Abstract][Full Text] [Related]
4. Tamoxifen resistance: from cell culture experiments towards novel biomarkers.
Nass N; Kalinski T
Pathol Res Pract; 2015 Mar; 211(3):189-97. PubMed ID: 25666016
[TBL] [Abstract][Full Text] [Related]
5. [Molecular aspects of different mechanisms of tamoxifen resistance].
Bachmann-Moisson N; Barberi-Heyob M; Merlin JL
Bull Cancer; 1997 Jan; 84(1):69-75. PubMed ID: 9180863
[TBL] [Abstract][Full Text] [Related]
6. Tamoxifen Resistance: Emerging Molecular Targets.
Rondón-Lagos M; Villegas VE; Rangel N; Sánchez MC; Zaphiropoulos PG
Int J Mol Sci; 2016 Aug; 17(8):. PubMed ID: 27548161
[TBL] [Abstract][Full Text] [Related]
7. GATA3 mRNA expression, but not mutation, associates with longer progression-free survival in ER-positive breast cancer patients treated with first-line tamoxifen for recurrent disease.
Liu J; Prager-van der Smissen WJ; Look MP; Sieuwerts AM; Smid M; Meijer-van Gelder ME; Foekens JA; Hollestelle A; Martens JW
Cancer Lett; 2016 Jun; 376(1):104-9. PubMed ID: 27018307
[TBL] [Abstract][Full Text] [Related]
8. Tamoxifen resistance in breast cancer: elucidating mechanisms.
Dorssers LC; Van der Flier S; Brinkman A; van Agthoven T; Veldscholte J; Berns EM; Klijn JG; Beex LV; Foekens JA
Drugs; 2001; 61(12):1721-33. PubMed ID: 11693462
[TBL] [Abstract][Full Text] [Related]
9. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer.
Berns EM; Foekens JA; Vossen R; Look MP; Devilee P; Henzen-Logmans SC; van Staveren IL; van Putten WL; Inganäs M; Meijer-van Gelder ME; Cornelisse C; Claassen CJ; Portengen H; Bakker B; Klijn JG
Cancer Res; 2000 Apr; 60(8):2155-62. PubMed ID: 10786679
[TBL] [Abstract][Full Text] [Related]
10. Relationship between intratumoral expression of genes coding for xenobiotic-metabolizing enzymes and benefit from adjuvant tamoxifen in estrogen receptor alpha-positive postmenopausal breast carcinoma.
Bièche I; Girault I; Urbain E; Tozlu S; Lidereau R
Breast Cancer Res; 2004; 6(3):R252-63. PubMed ID: 15084249
[TBL] [Abstract][Full Text] [Related]
11. Estrogen receptors in resistance to hormone therapy.
Herynk MH; Fuqua SA
Adv Exp Med Biol; 2007; 608():130-43. PubMed ID: 17993238
[TBL] [Abstract][Full Text] [Related]
12. A pure antiestrogen, ICI 182,780, stimulates the growth of tamoxifen-resistant KPL-1 human breast cancer cells in vivo but not in vitro.
Kurebayashi J; Otsuki T; Yamamoto S; Kurosumi M; Nakata T; Akinaga S; Sonoo H
Oncology; 1998 Dec; 55 Suppl 1():23-34. PubMed ID: 9852399
[TBL] [Abstract][Full Text] [Related]
13. Comparison of estrogen receptor DNA binding in untreated and acquired antiestrogen-resistant human breast tumors.
Johnston SR; Lu B; Dowsett M; Liang X; Kaufmann M; Scott GK; Osborne CK; Benz CC
Cancer Res; 1997 Sep; 57(17):3723-7. PubMed ID: 9288779
[TBL] [Abstract][Full Text] [Related]
14. Dual targeting of EphA2 and ER restores tamoxifen sensitivity in ER/EphA2-positive breast cancer.
Gökmen-Polar Y; Toroni RA; Hocevar BA; Badve S; Zhao Q; Shen C; Bruckheimer E; Kinch MS; Miller KD
Breast Cancer Res Treat; 2011 Jun; 127(2):375-84. PubMed ID: 20602165
[TBL] [Abstract][Full Text] [Related]
15. Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and β1-integrin signaling pathway in tumor cells.
Yuan J; Liu M; Yang L; Tu G; Zhu Q; Chen M; Cheng H; Luo H; Fu W; Li Z; Yang G
Breast Cancer Res; 2015 May; 17(1):69. PubMed ID: 25990368
[TBL] [Abstract][Full Text] [Related]
16. Tamoxifen-resistant breast cancers show less frequent methylation of the estrogen receptor beta but not the estrogen receptor alpha gene.
Chang HG; Kim SJ; Chung KW; Noh DY; Kwon Y; Lee ES; Kang HS
J Mol Med (Berl); 2005 Feb; 83(2):132-9. PubMed ID: 15536519
[TBL] [Abstract][Full Text] [Related]
17. MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen.
Brünner N; Boysen B; Jirus S; Skaar TC; Holst-Hansen C; Lippman J; Frandsen T; Spang-Thomsen M; Fuqua SA; Clarke R
Cancer Res; 1997 Aug; 57(16):3486-93. PubMed ID: 9270017
[TBL] [Abstract][Full Text] [Related]
18. Understanding resistance to tamoxifen in hormone receptor-positive breast cancer.
Higgins MJ; Stearns V
Clin Chem; 2009 Aug; 55(8):1453-5. PubMed ID: 19541862
[No Abstract] [Full Text] [Related]
19. Expression of estrogen receptor (ER) (beta)cx protein in ER(alpha)-positive breast cancer: specific correlation with progesterone receptor.
Saji S; Omoto Y; Shimizu C; Warner M; Hayashi Y; Horiguchi S; Watanabe T; Hayashi S; Gustafsson JA; Toi M
Cancer Res; 2002 Sep; 62(17):4849-53. PubMed ID: 12208729
[TBL] [Abstract][Full Text] [Related]
20. Progesterone receptor positivity is a predictor of long-term benefit from adjuvant tamoxifen treatment of estrogen receptor positive breast cancer.
Nordenskjöld A; Fohlin H; Fornander T; Löfdahl B; Skoog L; Stål O
Breast Cancer Res Treat; 2016 Nov; 160(2):313-322. PubMed ID: 27722840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
